These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23917464)

  • 1. Heart failure: Heart failure clinical trials: how do we define success?
    Ziaeian B; Fonarow GC
    Nat Rev Cardiol; 2013 Sep; 10(9):492-4. PubMed ID: 23917464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unbelievable Folly of Clinical Trials in Heart Failure: The Inconvenient Truth About How Investigators and Guidelines Weigh Evidence.
    Packer M
    Circ Heart Fail; 2016 Apr; 9(4):e002837. PubMed ID: 27009552
    [No Abstract]   [Full Text] [Related]  

  • 3. Pragmatic approaches to the next generation of clinical trials in heart failure.
    Lund LH
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):282-283. PubMed ID: 32667969
    [No Abstract]   [Full Text] [Related]  

  • 4. Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward.
    Eapen ZJ; Tang WH; Felker GM; Hernandez AF; Mahaffey KW; Lincoff AM; Roe MT
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):594-600. PubMed ID: 22811505
    [No Abstract]   [Full Text] [Related]  

  • 5. Bleeding definitions in orthopaedic VTE prophylaxis trials: a real need for standardization.
    Dahl OE
    Thromb Res; 2012 Oct; 130 Suppl 1():S32. PubMed ID: 23026656
    [No Abstract]   [Full Text] [Related]  

  • 6. Developing core outcome sets for clinical trials: issues to consider.
    Williamson PR; Altman DG; Blazeby JM; Clarke M; Devane D; Gargon E; Tugwell P
    Trials; 2012 Aug; 13():132. PubMed ID: 22867278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials.
    Ibrahim NE; Gaggin HK; Konstam MA; Januzzi JL
    Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27582282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The COMET Handbook: version 1.0.
    Williamson PR; Altman DG; Bagley H; Barnes KL; Blazeby JM; Brookes ST; Clarke M; Gargon E; Gorst S; Harman N; Kirkham JJ; McNair A; Prinsen CAC; Schmitt J; Terwee CB; Young B
    Trials; 2017 Jun; 18(Suppl 3):280. PubMed ID: 28681707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e302-4. PubMed ID: 15173052
    [No Abstract]   [Full Text] [Related]  

  • 10. 2018 EHRA expert consensus statement on lead extraction: recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: endorsed by APHRS/HRS/LAHRS.
    Bongiorni MG; Burri H; Deharo JC; Starck C; Kennergren C; Saghy L; Rao A; Tascini C; Lever N; Kutarski A; Fernandez Lozano I; Strathmore N; Costa R; Epstein L; Love C; Blomstrom-Lundqvist C;
    Europace; 2018 Jul; 20(7):1217. PubMed ID: 29566158
    [No Abstract]   [Full Text] [Related]  

  • 11. Examining the Influence of Component Outcomes on the Composite at the Design Stage.
    Brown PM; Ezekowitz JA
    Circ Cardiovasc Qual Outcomes; 2018 Jun; 11(6):e004419. PubMed ID: 29860234
    [No Abstract]   [Full Text] [Related]  

  • 12. Time-to-first-event versus recurrent-event analysis: points to consider for selecting a meaningful analysis strategy in clinical trials with composite endpoints.
    Rauch G; Kieser M; Binder H; Bayes-Genis A; Jahn-Eimermacher A
    Clin Res Cardiol; 2018 May; 107(5):437-443. PubMed ID: 29453594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure.
    Packer M
    J Card Fail; 2001 Jun; 7(2):176-82. PubMed ID: 11420770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Acute and chronic heart failure - innovations of the new ESC guidelines and their underlying clinical trials].
    Pöss J; Ewen S; Link A; Böhm M
    Dtsch Med Wochenschr; 2013 Jun; 138(25-26):1360-4. PubMed ID: 23761058
    [No Abstract]   [Full Text] [Related]  

  • 15. Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium.
    Abraham WT; Psotka MA; Fiuzat M; Filippatos G; Lindenfeld J; Mehran R; Ambardekar AV; Carson PE; Jacob R; Januzzi JL; Konstam MA; Krucoff MW; Lewis EF; Piccini JP; Solomon SD; Stockbridge N; Teerlink JR; Unger EF; Zeitler EP; Anker SD; O'Connor CM
    Eur J Heart Fail; 2020 Dec; 22(12):2175-2186. PubMed ID: 33017862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e305-7. PubMed ID: 15173053
    [No Abstract]   [Full Text] [Related]  

  • 17. Resynchronization therapy for the treatment of heart failure.
    Saxon LA; Ellenbogen KA
    Circulation; 2003 Sep; 108(9):1044-8. PubMed ID: 12952826
    [No Abstract]   [Full Text] [Related]  

  • 18. Timing and duration of interventions in clinical trials for patients with hospitalized heart failure.
    Marti CN; Fonarow GC; Gheorghiade M; Butler J
    Circ Heart Fail; 2013 Sep; 6(5):1095-101. PubMed ID: 24046476
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of nonrandomized trials in the evaluation of oncology drugs.
    Simon R; Blumenthal GM; Rothenberg ML; Sommer J; Roberts SA; Armstrong DK; LaVange LM; Pazdur R
    Clin Pharmacol Ther; 2015 May; 97(5):502-7. PubMed ID: 25676488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving outcome reporting in clinical trial reports and protocols: study protocol for the Instrument for reporting Planned Endpoints in Clinical Trials (InsPECT).
    Butcher NJ; Monsour A; Mew EJ; Szatmari P; Pierro A; Kelly LE; Farid-Kapadia M; Chee-A-Tow A; Saeed L; Monga S; Ungar W; Terwee CB; Vohra S; Fergusson D; Askie LM; Williamson PR; Chan AW; Moher D; Offringa M
    Trials; 2019 Mar; 20(1):161. PubMed ID: 30841935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.